Global Top 10 Cancer Drugs market to hit $198.8B by 2032 (10% CAGR). Fueled by rising cancer prevalence, aging population, and increased awareness.
WILMINGTON, DE, UNITED STATES, July 11, 2025 /EINPresswire.com/ — Allied Market Research published a report, titled, “Top 10 Cancer Drugs Market by Region (Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2018–2026.” According to the report, the global top 10 cancer drugs industry generated $63.61 billion in 2018, and is estimated to reach $129.94 billion by 2026, witnessing a CAGR of 9.8% from 2019 to 2026.
Cancer is caused when cells in the body grow excessively, leading to the formation of tumors. Cancer has different stages depending on its progress. Metastasis is the last stage of the disease, which is indicated by the invasion of the tumor into other parts of the body. The management of cancer patients requires the use of different types of drugs such as hormone therapy, immunotherapy, targeted therapy and others.
Major market players covered in the report, such as –
AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bristol-Myers Squibb Company
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Johnson & Johnson (Janssen Global Services, LLC)
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Key Benefits for Stakeholders –
• The report provides quantitative analysis of market segments, current trends, strategies and potential of top 10 cancer drugs market research to identify potential top 10 cancer drugs market opportunities in genetics.
• In-depth analysis of this sector helps identify current market opportunities.
• Market analysis and information related to key drivers, restraints and opportunities are provided.
• Porter’s Five Forces Analysis identifies the capabilities of buyers and suppliers to enable stakeholders to make profitable business decisions and strengthen the network of buyers.
• The largest countries in each region are listed according to their contribution to the global market.
• Focusing on market players makes benchmarking easier and provides a clear understanding of the current market situation.
• The report includes regional and global top 10 cancer drugs market analysis, key players, market segments, application areas and Market growth strategies.
Cancer is a medical condition in which abnormal cells develop and have the potential to invade or spread to other parts of the body. The cancer drug market is expected to show significant growth in the market during the forecast period due to the increase in the number of different types of cancer, increasing popularity of advanced treatments such as antibiotic therapy and goals, the development of research methods and the increase in the geriatric population worldwide. In addition, increasing R&D activities and availability of cancer drugs are expected to boost the market growth. It is expected that the high strength of the emerging economy and the number of products produced will provide new opportunities for future sellers. On the other hand, high cost associated with new drug development and side effects associated with cancer treatment are expected to restrain the market growth.
In the European region, the global market for the top 10 cancer drugs in Russia achieved the highest revenue at nearly $822.7 million in 2018 and will retain its highest share through 2026. In Asia-Pacific, Indonesian market achieved the highest market share. With revenue of nearly $995.25 million in 2018, it is expected to maintain its revenue potential during the forecast period. However, Nepal market is expected to maintain the highest CAGR of 11.4% from 2019 to 2026.
The top 10 cancer drugs market is expected to witness a significant growth in the coming years. This market has gained interest of the healthcare and medical sectors owing to increased prevalence of hypertension throughout the globe. Furthermore, the global top 10 cancer drugs market is segmented on the basis of product type, end user, and region. leading market players have been introducing various strategies to help enterprises move their on-premise models to on-demand models.
